Enterosgel Research Studies
-
ENTOPIC RCT: Now Recruiting: Children with Func...
The ENTOPIC RCT is an active, ongoing double-blind randomised controlled trial investigating the efficacy of Enterosgel® to relieve abdominal pain in children and young people aged 3–18 years with Functional...
ENTOPIC RCT: Now Recruiting: Children with Func...
The ENTOPIC RCT is an active, ongoing double-blind randomised controlled trial investigating the efficacy of Enterosgel® to relieve abdominal pain in children and young people aged 3–18 years with Functional...
-
2019: Scientific Reports: Adsorption of Bacteri...
A peer-reviewed laboratory study published in Scientific Reports (Nature Portfolio) in 2019 confirmed that Enterosgel® effectively adsorbs the bacterial toxins responsible for gut infection and diarrhoea — including C. difficile...
2019: Scientific Reports: Adsorption of Bacteri...
A peer-reviewed laboratory study published in Scientific Reports (Nature Portfolio) in 2019 confirmed that Enterosgel® effectively adsorbs the bacterial toxins responsible for gut infection and diarrhoea — including C. difficile...
-
2025: BMJ Paediatrics: The Gambia Children Study
BMJ Paediatrics Open · 2025 Randomised Feasibility Study of an Intestinal Adsorbent in Acute Diarrhoea in The Gambia Prof. Stephen Allen · Dr Paul Rahden · BMJ Paediatrics Open · ...
2025: BMJ Paediatrics: The Gambia Children Study
BMJ Paediatrics Open · 2025 Randomised Feasibility Study of an Intestinal Adsorbent in Acute Diarrhoea in The Gambia Prof. Stephen Allen · Dr Paul Rahden · BMJ Paediatrics Open · ...
-
2019: BMJ Open Gastroenterology: Acute Diarrhoea
A randomised controlled trial published in BMJ Open Gastroenterology in 2019 demonstrated that Enterosgel® significantly reduces the duration of acute diarrhoea in adults in a primary care setting. Led by...
2019: BMJ Open Gastroenterology: Acute Diarrhoea
A randomised controlled trial published in BMJ Open Gastroenterology in 2019 demonstrated that Enterosgel® significantly reduces the duration of acute diarrhoea in adults in a primary care setting. Led by...
-
2024 : The Lancet Gastroenterology & Hepatology...
In 2024, Professor Alexander Ford and Dr Christopher Black published a landmark personalised therapy review in The Lancet Gastroenterology & Hepatology recommending Enterosgel® as a first-line treatment for IBS patients...
2024 : The Lancet Gastroenterology & Hepatology...
In 2024, Professor Alexander Ford and Dr Christopher Black published a landmark personalised therapy review in The Lancet Gastroenterology & Hepatology recommending Enterosgel® as a first-line treatment for IBS patients...
-
2022: The Gut Journal: RELIEVE IBS-D Double-Bli...
The RELIEVE IBS-D trial is the largest randomised controlled trial of Enterosgel® ever conducted — 440 patients, 28 NHS sites, double-blind, placebo-controlled. Published in GUT journal in 2022 and named...
2022: The Gut Journal: RELIEVE IBS-D Double-Bli...
The RELIEVE IBS-D trial is the largest randomised controlled trial of Enterosgel® ever conducted — 440 patients, 28 NHS sites, double-blind, placebo-controlled. Published in GUT journal in 2022 and named...
